Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Saved in:
| Title: | Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. |
|---|---|
| Authors: | Montoya S; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Bourcier J; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Noviski M; Nurix Therapeutics, San Francisco, CA, USA., Lu H; Nurix Therapeutics, San Francisco, CA, USA., Thompson MC; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chirino A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Jahn J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Sondhi AK; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Gajewski S; Nurix Therapeutics, San Francisco, CA, USA., Tan YSM; Nurix Therapeutics, San Francisco, CA, USA., Yung S; Nurix Therapeutics, San Francisco, CA, USA., Urban A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Wang E; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Han C; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Mi X; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kim WJ; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sievers Q; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Auger P; Nurix Therapeutics, San Francisco, CA, USA., Bousquet H; Nurix Therapeutics, San Francisco, CA, USA., Brathaban N; Nurix Therapeutics, San Francisco, CA, USA., Bravo B; Nurix Therapeutics, San Francisco, CA, USA., Gessner M; Nurix Therapeutics, San Francisco, CA, USA., Guiducci C; Nurix Therapeutics, San Francisco, CA, USA., Iuliano JN; Nurix Therapeutics, San Francisco, CA, USA., Kane T; Nurix Therapeutics, San Francisco, CA, USA., Mukerji R; Nurix Therapeutics, San Francisco, CA, USA., Reddy PJ; Nurix Therapeutics, San Francisco, CA, USA., Powers J; Nurix Therapeutics, San Francisco, CA, USA., Sanchez Garcia de Los Rios M; Nurix Therapeutics, San Francisco, CA, USA., Ye J; Nurix Therapeutics, San Francisco, CA, USA., Barrientos Risso C; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Tsai D; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Pardo G; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Notti RQ; Laboratory of Molecular Electron Microscopy, Rockefeller University, New York, NY, USA., Pardo A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Affer M; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Nawaratne V; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Totiger TM; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Pena-Velasquez C; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rhodes JM; Division of Hematology-Oncology, Department of Medicine at Zucker School of Medicine at Hofstra/Northwell, CLL Research and Treatment Center, Lake Success, NY, USA., Zelenetz AD; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Alencar A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Roeker LE; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mehta S; Gene Editing and Screening Core Facility, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Institute and Cancer Center, New York, NY, USA., Garippa R; Gene Editing and Screening Core Facility, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Institute and Cancer Center, New York, NY, USA., Linley A; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK., Soni RK; Proteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA., Skånland SS; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Brown RJ; Nurix Therapeutics, San Francisco, CA, USA., Mato AR; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hansen GM; Nurix Therapeutics, San Francisco, CA, USA., Abdel-Wahab O; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Taylor J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. |
| Source: | Science (New York, N.Y.) [Science] 2024 Feb 02; Vol. 383 (6682), pp. eadi5798. Date of Electronic Publication: 2024 Feb 02. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-9203 (Electronic) Linking ISSN: 00368075 NLM ISO Abbreviation: Science Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1095-9203 |
|---|---|
| DOI: | 10.1126/science.adi5798 |
